Two hundred and sixty one patients with CMML were included in the study. All patients had bone marrow (BM) biopsies and cytogenetics performed at diagnosis. Targeted capture assays were carried out on BM DNA specimens obtained at diagnosis for the following genes: TET2, DNMT3A, IDH1, IDH2, ASXL1, EZH2, SUZ12, SRSF2, SF3B1, ZRSR2, U2AF1, PTPN11, Tp53, SH2B3, RUNX1, CBL, NRAS, KRAS, JAK2, CSF3R, FLT3, KIT, CALR, MPL, NPM1, CEBPA, IKZF and SETBP1, by previously described methods.
1 TET2 (NM_001127208.2) coverage extended from exons 3-11, with frame shift, nonsense and missense variations considered pathogenic. Previously annotated single nucleotide polymorphisms (http//www.hapmap.org) were considered non-pathogenic. The 2008 and 2016 World Health Organization (WHO) criteria were used for CMML diagnosis and classification. 5 Among the 261 study patients, 65% were males and median age was 70 years (range, 28-91). One hundred and fifty four (59%), 64 (25%) and 43 (16%) patients were classified as CMML-0, 1 and 2, respectively. At a median follow-up of 23 months, 174 (67%) deaths and 37 (14%) leukemic transformations were documented. Mutational frequencies included: ASXL1 45%, TET2 43%, SRSF2 40%, NRAS 14%, SETBP1 13%, CBL 10%, JAK2 7%, RUNX1 6%, Next-generation sequencing analysis; n (%) Epigenetic regulators Letter to the Editor DNMT3A 6%, U2AF1 6%, SF3B1 5%, ZRSR2 4%, Tp53 4%, IDH2 4%, KRAS 3%, c-KIT 3%, PTPN11 3% and o 1% each for FLT3ITD, CALR and MPL. There were no IKZF, STAG2 or SH2B3 mutations seen. Two hundred and sixty four TET2 mutations were seen in 113 (43%) patients; these included 34 (30%) patients with frameshift, 30 (27%) with nonsense and 13 (10%) with missense mutations, whereas 36 (33%) patients had more than one type of mutation ( Figure 1) . Overall, 58 (52%) patients had more than 1 TET2 mutation: 55 (49%) patients had 1, 47 (41%) had 2 and 11 (10%) had ⩾ 3 TET2 mutations. The median variant allelic fractions (VAF) for TET2 mutations included; frameshift 43% (range, 10-92%), nonsense 47% (range, 9-100%) and missense 47% (range, 14-95%), respectively. Among the 113 TET2 mutated patients, 65% were males, and median age was 71 years with no significant difference in age and gender distribution between mutated and un-mutated cases, or type of TET2 mutations; however, older patients were more likely to carry multiple TET2 mutations (P = 0.01) ( Table 1 ). The frequency distribution of TET2 mutations with age was: o50 years n = 15 (6%), 50-59 years n = 25 (10%), 60-69 years n = 83 (31%), 70-79 years n = 104 (39%) and ⩾ 80 years n = 37 (14%), respectively. The cytosine-to-thymidine (C:G4 T:A) base pair change (transition) is often considered a somatic mutational signature of ageing. 6, 7 In this cohort, C4T base pair changes proportionally comprised, 0% o50 years, 18% 50-60 years, 44% 60-69 years, 41% 70-79 years and 50% ⩾ 80 years. In addition, 73% of patients with TET2 C4T base pair changes had more than one TET2 mutation. DNMT3A mutations significantly clustered with TET2 C4T base pair changes (P = 0.03), with 5 of 6 (83%) DNMT3A-mutated patients having concomitant TET2 C4T base pair changes. Incidentally, only 2 of 6 (33%) DNMT3A mutations themselves were as a result of C4T base pair changes.
Compared with their un-mutated counterparts, TET2-mutated cases were less likely to have a low hemoglobin (P o0.001), include CMML-2 (P = 0.007), have circulating immature myeloid cells (P = 0.001), have peripheral blood (P = 0.009) and BM blasts (P = 0.009), and have higher-risk stratification per clinical, cytogenetic and molecularly inclusive CMML prognostic models (Table 1) ; these differences were not affected by the type or number of TET2 mutations. TET2 mutated cases were more likely to have a higher frequency of SRSF2 (P = 0.004) and a lower frequency of ASXL1 (P = 0.03), Tp53 (P = 0.04) and IDH1/2 mutations (P o 0.001); these associations were also not affected by the type or number of TET2 mutations.
Median survival for the entire cohort (n = 261) was 24 months. In univariate analysis, survival was superior in TET2-mutated (median 33 months) versus wild-type (median 21 months) patients (P = 0.03; HR 1.3 95% CI 1.12-1.86). This survival difference remained significant after adjustment for age (P = 0.04), leukocyte count (P = 0.017), absolute monocyte count (P = 0.02), absolute lymphocyte count (P = 0.02), platelet count (P = 0.015), circulating immature myeloid cells (P = 0.03), DNMT3A (P = 0.02) and ASXL1 (P = 0.045) mutations; however, significance was lost after adjustment for abnormal karyotype (P = 0.32) and the Mayo Molecular Model (P = 0.0003). These observations were not affected by the type or number of TET2 mutations. Finally, our previous observation regarding the survival advantage of ASXL1wt/TET2mt versus other genotypes was most apparent for patients with multiple TET2 mutations (P = 0.02).
1
TET2 mutations are frequent in CMML (~45%) and constitute approximately equal proportions of frameshift and nonsense mutations, while missense mutations are less frequent. Majority of TET2-mutated CMML cases harbor more than one mutant variant. Regardless, the relevance of type and number of TET2 mutations in CMML was limited to an association between older age and number of mutations, and the latter with possibly improved survival in the absence of clonal ASXL1 mutations.
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